Alzheimer's drug update
Harvard researchers help test new drugs that could strike at the root of Alzheimer's disease. Here's where things stand.
In October 2012, scientists at the American Neurological Association (ANA) meeting in Boston presented the latest findings on a new generation of Alzheimer's medications. These drugs are designed to fight the build-up of abnormal amyloid protein in the brains of people with Alzheimer's disease. Experts hope that blocking amyloid will delay or possibly even stop the progression of the illness.
The results of testing on the new anti-amyloid drugs, bapineuzu-mab and solanezumab, were disappointing: neither met the stringent standards for FDA approval as a treatment for people with mild to moderate Alzheimer's disease.
But the studies also offered reasons to be hopeful about new trials of anti-amyloid drugs, starting in 2013.